RXi Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
RXi has developed a proprietary self-delivering RNAi (sd-rxRNA) platform proven to be safe and well tolerated in a clinical setting. The Company's novel compounds have the potential to selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. Dr. Dispersyn will present a corporate overview that includes the Company's immuno-oncology, dermatology and ophthalmology programs.
Room: Track 3, St. Germain
The presentation will be available under the "Investors – Events and Presentations" section of the Company's website, www.rxipharma.com approximately 1 hour following the presentation.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors." Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.